Back to News
Market Impact: 0.15
Sangamo Plans Sale Of ST-503 For Neuropathic Pain By Q4 '26 Following Chapter 11 Filing
Source: Nasdaq
Healthcare & BiotechM&A & Restructuring
Sangamo Therapeutics announced a timeline for the sale of ST-503, an epigenetics regulator being developed to treat intractable pain in small fibre neuropathy. The provided article text ends before giving the timeline, sale terms, or other details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
SGMOQ0.10
More News
- UBS considers leaving Switzerland over capital rule plans, WSJ reports
- Bending Spoons skyrockets 35% as Berkshire Hathaway makes $330 million investment
- Bending Spoons Stock Soars on Berkshire’s Increased Stake
- Travis Kelce joined an activist group pushing Six Flags to consider a sale. The ‘Final Destination’-style death of a patron poured gas on the fire
- Ambani’s Jio seeks to raise $3.2B in what could be India’s biggest IPO
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What a Concept From Nature Tells Us About How C-Suite Executives Actually Think About AI
- How to Track Earnings Call Sentiment Across Companies